• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Kronos Bio Inc (NQ: KRON )

    0.8500 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Kronos Bio Inc

    < Previous 1 2 Next >
    Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
    – Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity – 
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Announces Participation in Medical and Investor Conferences in September
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Reports First-Quarter 2024 Financial Results
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
    Company eliminates three executive officer roles and appoints new Executive Leadership team 
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13
    Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope 
    From Kronos Bio, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.